299 related articles for article (PubMed ID: 15283150)
1. [Rituximab and hematological malignancy].
Hatake K; Mishima Y; Terui Y
Nihon Rinsho; 2004 Jul; 62(7):1321-4. PubMed ID: 15283150
[TBL] [Abstract][Full Text] [Related]
2. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
6. [Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Tobinai K
Nihon Rinsho; 2002 Mar; 60(3):468-72. PubMed ID: 11904960
[TBL] [Abstract][Full Text] [Related]
7. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
8. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
10. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
11. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
Davis TA; Czerwinski DK; Levy R
Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
13. Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.
Horvat M; Kloboves Prevodnik V; Lavrencak J; Jezersek Novakovic B
Oncol Rep; 2010 Oct; 24(4):1101-7. PubMed ID: 20811695
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab in the treatment of B-cell non-Hodgkin lymphoma].
Mitrović Z; Aurer I
Lijec Vjesn; 2006; 128(1-2):36-42. PubMed ID: 16640226
[TBL] [Abstract][Full Text] [Related]
16. [Rituximab].
Okamoto R; Maeda Y; Sasaki T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
[TBL] [Abstract][Full Text] [Related]
17. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
[TBL] [Abstract][Full Text] [Related]
18. Empowering targeted therapy: lessons from rituximab.
Olszewski AJ; Grossbard ML
Sci STKE; 2004 Jul; 2004(241):pe30. PubMed ID: 15252219
[TBL] [Abstract][Full Text] [Related]
19. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
20. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]